Aptose Biosciences Stock Price

0.03 (0.91%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Aptose Biosciences Inc APTO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.03 0.91% 3.34 17:50:35
Open Price Low Price High Price Close Price Prev Close
3.35 3.285 3.37 3.34 3.31
Bid Price Ask Price Spread News
3.34 3.35 0.01 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
6,103 1,040,674 $ 3.32 $ 3,458,891 1,355,579 3.22 - 7.30
Last Trade Time Type Quantity Stock Price Currency
19:38:38 40 $ 3.35 USD

Aptose Biosciences Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 292.20M 87.48M 41.07M $ - $ - -0.84 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - -

more financials information »

Aptose Biosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical APTO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.5183.603.223.381,666,835-0.178-5.06%
1 Month5.165.78273.223.981,840,656-1.82-35.27%
3 Months6.,243,499-2.89-46.39%
6 Months4.,697,438-0.87-20.67%
1 Year6.937.303.225.391,948,184-3.59-51.8%
3 Years4.059.25251.575.14999,516-0.71-17.53%
5 Years2.429.25250.784.54744,8000.9238.02%

Aptose Biosciences Description

Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. CG026806 (CG-806), its panFMS-like tyrosine kinase 3 / pan-Bruton's tyrosine kinase inhibitor, is enrolling patients in a Phase 1, multicenter, open label, dose-escalation study with expansions to assess the safety, tolerability, PK, and preliminary efficacy of CG-806 in patients with chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL).

Your Recent History
Aptose Bio..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.